日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial

随机概念验证 II 期试验,比较基于肿瘤分子分析的靶向治疗与难治性癌症患者的常规治疗:SHIVA 试验可行性部分的结果

C Le Tourneau, X Paoletti, N Servant, I Bièche, D Gentien, T Rio Frio, A Vincent-Salomon, V Servois, J Romejon, O Mariani, V Bernard, P Huppe, G Pierron, F Mulot, C Callens, J Wong, C Mauborgne, E Rouleau, C Reyes, E Henry, Q Leroy, P Gestraud, P La Rosa, L Escalup, E Mitry, O Trédan, J-P Delord, M

Bax expression is a candidate prognostic and predictive marker of colorectal cancer

Bax表达是结直肠癌的候选预后和预测标志物。

Katkoori, Venkat R; Suarez-Cuervo, Catalina; Shanmugam, Chandrakumar; Jhala, Nirag C; Callens, Tom; Messiaen, Ludwine; Posey, James 3rd; Bumpers, Harvey L; Meleth, Sreelatha; Grizzle, William E; Manne, Upender